During the first quarter, the Global Women’s Leadership portfolio lagged global developed market equities overall in the ...

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Gilead was putting the two drugs through their paces in a series of clinical trials, which were at various stages. The ones in the mid-to-late cycles were testing the pair against its currently ...

Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET. Company Participants. Daniel P. O'Day - Chairman & CEO. Confe ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Shares of Gilead Sciences Inc. GILD shed 2.58% to $110.09 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.55% to 6,038.81 ...

This was the stock's second consecutive day of gains.

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Gilead Sciences has announced that the U.S. Food and Drug Administration has placed a clinical hold on its HIV treatment ...